Program
HS-10542
A development code. Also written as “HS-10542 High Dose” and “HS-10542 Low Dose”.
In Hansoh Pharmaceutical Group's pipeline, factor B
. Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, IGA, led by Hansoh Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 33 open or running | phase 2since Jan 26, 2026 | May 8, 2025 | May 30, 2027phase 2 · NCT07470762 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-10542 (factor B)
, phase 2, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 8, 2025First study: phase 1 study in HealthyFirst studyNCT07040046 · 100 planned · China
- Jan 26, 2026Phase 2 study in Hemoglobinuria, ParoxysmalPhase 2 reachedNCT07470762 · 50 planned · China
- Feb 26, 2026Phase 2 study in Glomerulonephritis, IGANCT07474636 · 90 planned · China
Ahead
- May 30, 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT07470762
- Dec 10, 2027Primary completion: phase 2 study in Glomerulonephritis, IGANCT07474636
TargetBeta
“factor B”the company's pipeline, read by Claude · source
Other programs on CFB
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07474636Glomerulonephritis, IGA · China | 2 | Not yet recruiting | Dec 10, 2027 | 90 |
| NCT07470762Hemoglobinuria, Paroxysmal · China | 2 | Recruiting | May 30, 2027 | 50 |
| NCT07040046Healthy · China | 1 | Recruiting | Dec 4, 2025 | 100 |
How it is read
Names in the registry
- “HS-10542”, 5 entries
- “HS-10542 High Dose”, 1 entry
- “HS-10542 Low Dose”, 1 entry
Codes read as this program: HS10542.
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 1 study
- Glomerulonephritis, IGA, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.